Cargando…
Nanotechnology-enabled immunoengineering approaches to advance therapeutic applications
Immunotherapy has reached clinical success in the last decade, with the emergence of new and effective treatments such as checkpoint blockade therapy and CAR T-cell therapy that have drastically improved patient outcomes. Still, these therapies can be improved to limit off-target effects, mitigate s...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Nature Singapore
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047473/ https://www.ncbi.nlm.nih.gov/pubmed/35482149 http://dx.doi.org/10.1186/s40580-022-00310-0 |
_version_ | 1784695734222716928 |
---|---|
author | Chuang, Skylar T. Conklin, Brandon Stein, Joshua B. Pan, George Lee, Ki-Bum |
author_facet | Chuang, Skylar T. Conklin, Brandon Stein, Joshua B. Pan, George Lee, Ki-Bum |
author_sort | Chuang, Skylar T. |
collection | PubMed |
description | Immunotherapy has reached clinical success in the last decade, with the emergence of new and effective treatments such as checkpoint blockade therapy and CAR T-cell therapy that have drastically improved patient outcomes. Still, these therapies can be improved to limit off-target effects, mitigate systemic toxicities, and increase overall efficacies. Nanoscale engineering offers strategies that enable researchers to attain these goals through the manipulation of immune cell functions, such as enhancing immunity against cancers and pathogens, controlling the site of immune response, and promoting tolerance via the delivery of small molecule drugs or biologics. By tuning the properties of the nanomaterials, such as size, shape, charge, and surface chemistry, different types of immune cells can be targeted and engineered, such as dendritic cells for immunization, or T cells for promoting adaptive immunity. Researchers have come to better understand the critical role the immune system plays in the progression of pathologies besides cancer, and developing nanoengineering approaches that seek to harness the potential of immune cell activities can lead to favorable outcomes for the treatment of injuries and diseases. |
format | Online Article Text |
id | pubmed-9047473 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Nature Singapore |
record_format | MEDLINE/PubMed |
spelling | pubmed-90474732022-04-28 Nanotechnology-enabled immunoengineering approaches to advance therapeutic applications Chuang, Skylar T. Conklin, Brandon Stein, Joshua B. Pan, George Lee, Ki-Bum Nano Converg Review Immunotherapy has reached clinical success in the last decade, with the emergence of new and effective treatments such as checkpoint blockade therapy and CAR T-cell therapy that have drastically improved patient outcomes. Still, these therapies can be improved to limit off-target effects, mitigate systemic toxicities, and increase overall efficacies. Nanoscale engineering offers strategies that enable researchers to attain these goals through the manipulation of immune cell functions, such as enhancing immunity against cancers and pathogens, controlling the site of immune response, and promoting tolerance via the delivery of small molecule drugs or biologics. By tuning the properties of the nanomaterials, such as size, shape, charge, and surface chemistry, different types of immune cells can be targeted and engineered, such as dendritic cells for immunization, or T cells for promoting adaptive immunity. Researchers have come to better understand the critical role the immune system plays in the progression of pathologies besides cancer, and developing nanoengineering approaches that seek to harness the potential of immune cell activities can lead to favorable outcomes for the treatment of injuries and diseases. Springer Nature Singapore 2022-04-28 /pmc/articles/PMC9047473/ /pubmed/35482149 http://dx.doi.org/10.1186/s40580-022-00310-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Review Chuang, Skylar T. Conklin, Brandon Stein, Joshua B. Pan, George Lee, Ki-Bum Nanotechnology-enabled immunoengineering approaches to advance therapeutic applications |
title | Nanotechnology-enabled immunoengineering approaches to advance therapeutic applications |
title_full | Nanotechnology-enabled immunoengineering approaches to advance therapeutic applications |
title_fullStr | Nanotechnology-enabled immunoengineering approaches to advance therapeutic applications |
title_full_unstemmed | Nanotechnology-enabled immunoengineering approaches to advance therapeutic applications |
title_short | Nanotechnology-enabled immunoengineering approaches to advance therapeutic applications |
title_sort | nanotechnology-enabled immunoengineering approaches to advance therapeutic applications |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047473/ https://www.ncbi.nlm.nih.gov/pubmed/35482149 http://dx.doi.org/10.1186/s40580-022-00310-0 |
work_keys_str_mv | AT chuangskylart nanotechnologyenabledimmunoengineeringapproachestoadvancetherapeuticapplications AT conklinbrandon nanotechnologyenabledimmunoengineeringapproachestoadvancetherapeuticapplications AT steinjoshuab nanotechnologyenabledimmunoengineeringapproachestoadvancetherapeuticapplications AT pangeorge nanotechnologyenabledimmunoengineeringapproachestoadvancetherapeuticapplications AT leekibum nanotechnologyenabledimmunoengineeringapproachestoadvancetherapeuticapplications |